Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study

Alberto Garaventa; Ulrike Pöetschger; Dominique Valteau‐Couanet; Roberto Luksch; Victoria Castel; Martin Elliott; Shifra Ash; Gcf Chan; Geneviève Laureys; Maja Beck‐Popovic; Kim Vettenranta; Walentyna Balwierz; Henrik Schrøeder; Cormac Owens; Maja Česen; Vassilios Papadakis; Toby N. Trahair; Gudrun Schleiermacher; Peter F. Ambros; Stefania Sorrentino; Andrew D.J. Pearson; Ruth Ladenstein

doi:10.1200/jco.20.03144

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

No difference in outcome was observed between rCOJEC and MSKCC-N5; however, acute toxicity was less with rCOJEC, and therefore rCOJEC is the preferred induction regimen for International Society of Pediatric Oncology European Neuroblastoma Group.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Garaventa et al. (2021) studied this question.

synapsesocial.com/papers/69dd6070ae7c4d5b29100f06 https://doi.org/10.1200/jco.20.03144

View Full Paper

Ask AI

Bookmark

Share

Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study

Ask about this paper

Abstract

Discussion

Cite This Study

Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading